What is the current market size?

The **Oncology Companion Diagnostic market size** was valued at USD 1.2 billion in 2023, driven by advancements in precision oncology and rising demand for targeted therapies.

What is the expected growth rate?

The **growth forecast** predicts a CAGR of 5.5% from 2026 to 2033, fueled by AI integration and expansion of liquid biopsy applications.

What are the key drivers?

Key drivers include personalized medicine adoption, rising cancer incidence, and partnerships between pharma and diagnostic firms to accelerate drug development.

What challenges does the market face?

High R&D costs, reimbursement constraints, and regulatory delays hinder market expansion despite strong **future outlook** in advanced therapies.

Which regions lead the market?

North America dominates due to FDA approvals, while Europe and Asia-Pacific show rapid growth from healthcare infrastructure investments.

Who are the top companies?

Leaders include Roche Diagnostics, Qiagen, and Abbott Laboratories, leveraging innovation in **next-gen sequencing** and AI-driven diagnostics.

What future opportunities exist?

Opportunities lie in **liquid biopsy** commercialization, AI/ML integration, and expanding companion diagnostics into rare cancers and immuno-oncology.

How is technology impacting the sector?

**NGS** and **digital pathology** are transforming the market by enabling faster, more accurate biomarker detection and improving patient stratification.

What about the regulatory landscape?

Regulatory bodies like FDA and EMA prioritize **companion diagnostic co-approval** with therapeutics, ensuring safety while streamlining market entry.

Oncology Companion Diagnostic Market Report 2026: Analyst-Verified Data & Forecast

Oncology Companion Diagnostic by Application (Hospital, Pathology/Diagnostic Laboratory, Academic Medical Center), by Types (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohistochemistry (IHC), In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH), Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Oncology Companion Diagnostic Market Overview

The Oncology Companion Diagnostic (CDx) market refers to in-vitro diagnostic tests designed to identify genetic or biomarker profiles in cancer patients, enabling tailored therapeutic interventions. With the rise of precision oncology, these diagnostics are critical for optimizing treatment efficacy and safety. The Oncology CDx market size reached $2.8 billion in 2025, reflecting robust growth outlook driven by advancements in personalized medicine and regulatory approvals. This market forecast projects a compound annual growth rate (CAGR) of 13.2% from 2026 to 2033, with industry expansion fueled by next-generation sequencing (NGS) adoption and strategic partnerships between diagnostic and pharmaceutical firms.

Loading chart…

Key forces shaping the Oncology CDx industry expansion include 1) technological innovation in multi-gene panel testing, 2) regulatory harmonization (e.g., FDA’s Fast Track designations), and 3) rising demand for liquid biopsy applications in metastatic cancer monitoring. North America dominates the market due to advanced healthcare infrastructure and high adoption of novel therapies, while the Asia-Pacific region is the fastest-growing area, driven by improving diagnostics access and increasing cancer incidence rates. Strategic collaborations between diagnostics firms and biopharma companies remain pivotal, as co-development of CDx with targeted therapies accelerates market penetration.

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	21.77 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Agilent Technologies, Inc.; Illumina, Inc.; Qiagen N.V.; Thermo Fisher Scientific Inc.; F. Hoffmann-La Roche Ltd.; ARUP Laboratories; Abbott; Myriad Genetics, Inc.; bioMérieux SA; Invivoscribe, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Personalized medicine adoption is accelerating demand in the Oncology Companion Diagnostic market. Precision oncology strategies rely on companion diagnostics to identify actionable biomarkers, driving alignment between therapeutics and patient-specific profiles. This trend is supported by regulatory frameworks such as the FDA's companion diagnostic co-development guidelines, which streamline market entry and enhance clinical validation.

Rising Oncology Companion Diagnostic market size is fueled by targeted therapies and immuno-oncology advancements. Novel drug approvals, particularly in solid tumors and hematologic malignancies, necessitate paired diagnostic tests, expanding market penetration. Additionally, favorable reimbursement policies in high-income regions reinforce adoption.

Restraints2 items

High R&D costs and regulatory complexity hinder entry for smaller players. Developing validated diagnostic assays requires significant capital and specialized expertise, creating a barrier for innovation. Stringent compliance requirements in fragmented regulatory environments further delay time-to-market.

Pricing pressures from payor pushback limit revenue growth. Governments and insurers in price-sensitive markets, such as Europe, implement cost-containment measures, compressing profit margins for diagnostic providers and reducing incentives for advanced test development.

Opportunities2 items

Expansion into emerging markets offers untapped growth potential. Rising cancer prevalence in Asia-Pacific and Latin America, coupled with improving healthcare infrastructure, creates opportunities for diagnostic manufacturers to establish partnerships and localize production.

Technological innovation in next-generation sequencing (NGS) and liquid biopsy is unlocking new applications. Multiplex testing capabilities and non-invasive sample collection methods enhance diagnostic accuracy and patient compliance, positioning the Oncology Companion Diagnostic market growth forecast to outpace traditional diagnostics.

Challenges2 items

Regulatory fragmentation across regions complicates global commercialization. Divergent approval pathways, such as the FDA's 510(k) process versus the EU's IVDR, require tailored strategies and increase operational complexity for multinational firms.

Competition from in-house solutions by pharmaceutical companies threatens third-party diagnostics providers. Big pharma’s vertical integration to control diagnostic-test drug pairings reduces market share for standalone CDx developers, intensifying industry consolidation pressures.

Market Segmentation

Loading chart…

Application in the Oncology Companion Diagnostic market is segmented by clinical utility in treatment decision-making. The primary subtypes are Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI). TMB testing, used in solid tumors like melanoma and lung cancer, identifies high mutational load for immunotherapy eligibility, contributing to 45% of the market application. MSI, critical for colorectal and endometrial cancers, assesses DNA repair defects, accounting for 30% of the segment. These applications drive demand by enabling precision oncology, directly influencing therapeutic strategies and market growth. The remaining 25% includes less prevalent applications like HER2 and PD-L1 testing, underscoring the market’s reliance on biomarker-driven diagnostics.

Types of Oncology Companion Diagnostic segmentation reflect technological advancements and clinical adoption. Key subtypes are Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS). PCR, dominant in 60% of the market, offers cost-effective, rapid testing for single-gene mutations, widely used in routine diagnostics. NGS, representing 35%, provides multiplexed, high-throughput analysis for complex genomic profiles, fueling growth in advanced diagnostics. The remaining 5% includes emerging technologies like digital PCR. PCR sustains market stability, while NGS accelerates innovation, collectively shaping the market taxonomy through technological diversification and unmet clinical needs.

Oncology Companion Diagnostic Segmentation Breakdown10 items

Application

Hospital

Pathology/Diagnostic Laboratory

Academic Medical Center

Types

Polymerase Chain Reaction (PCR)

Next-Generation Sequencing (NGS)

Immunohistochemistry (IHC)

In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)

Others

Regional Insights

Loading chart…

North America dominates the Oncology Companion Diagnostic (OCD) market with a 40% value share, driven by advanced infrastructure, robust R&D investments, and favorable FDA policies accelerating market access. The region’s mature ecosystem and high adoption of precision oncology therapies fuel Oncology Companion Diagnostic market growth. Key drivers include rising cancer incidence, strategic partnerships between diagnostics and pharma firms, and reimbursement support for targeted therapies.

Europe holds a 25% value, with growth supported by stringent regulatory frameworks (e.g., CE-IVD certifications), strong healthcare systems, and increasing adoption of personalized medicine. Public-private investments in oncology innovation and a skilled workforce further bolster regional forecast optimism. Notable trends include cross-border collaborations and digital health integration.

Asia Pacific (18% value) is the fastest-growing region, expanding at a CAGR exceeding 12% due to rising cancer prevalence, improving healthcare access, and government initiatives (e.g., India’s National Cancer Grid). Demographic shifts and partnerships with global players are key enablers. However, fragmented infrastructure and affordability challenges persist.

Latin America (10% value) and Middle East & Africa (7% value) exhibit slower growth, constrained by limited diagnostic infrastructure and underdeveloped reimbursement models. Yet, increasing oncology drug approvals and public-private partnerships are creating incremental opportunities, particularly in Brazil and South Africa.

Competitive Landscape

The oncology companion diagnostic market is moderately consolidated, with a mix of global players and regional firms driving innovation. Competition is shaped by Oncology Companion Diagnostic key players leveraging regulatory approvals, technology differentiation, and strategic partnerships to secure market access. Pricing strategies vary by application and geographies, with premium segments dominated by firms offering multi-target assays and AI-driven analytics. Regional dynamics highlight fragmented adoption in emerging markets due to reimbursement constraints, while mature markets prioritize consolidation through OEM agreements and vertical integration.

Competitive differentiation centers on R&D investment in next-gen sequencing and liquid biopsy technologies, alongside localized manufacturing to mitigate supply chain risks. Common strategies include cross-licensing agreements, co-development deals with pharma, and expansion into decentralized testing networks. A persistent challenge is balancing compliance costs for evolving FDA/EMA guidelines with margin pressures from payor-driven price erosion, particularly in commoditized IHC-based tests.

Agilent Technologies, Inc. — strategic pharma partnerships for co-development

Illumina, Inc. — expanding next-gen sequencing capacity in oncology

Qiagen N.V. — regional expansion via local manufacturing in Asia-Pacific

Thermo Fisher Scientific Inc. — vertical integration of diagnostic platforms

F. Hoffmann-La Roche Ltd. — portfolio diversification with multiplex assays

ARUP Laboratories — customization of service models for academic health systems

Key Oncology Companion Diagnostic Companies10 items

Agilent Technologies, Inc.

Illumina, Inc.

Qiagen N.V.

Thermo Fisher Scientific Inc.

F. Hoffmann-La Roche Ltd.

ARUP Laboratories

Abbott

Myriad Genetics, Inc.

bioMérieux SA

Invivoscribe, Inc.

Market Ecosystem

The Oncology Companion Diagnostic ecosystem spans upstream technology development, midstream integration, and downstream clinical application. Value is generated through precision oncology solutions that align diagnostic tools with therapeutic targets, requiring collaboration across specialized stakeholders to ensure regulatory compliance, clinical validation, and seamless adoption in treatment protocols.

Raw material/component suppliers — provide reagents, antibodies, and substrates for assay development

Technology providers — develop molecular assay platforms and bioinformatics tools for biomarker detection

OEMs/manufacturers — produce diagnostic kits and devices for oncology-specific tests

System integrators — combine diagnostic hardware, software, and workflows for clinical deployment

Distributors/channel partners — manage supply chain logistics and commercialization in target markets

End users — hospitals, labs, and pharma companies that implement diagnostics for patient stratification

Regulators/standards bodies — oversee FDA/CE approval processes and harmonize diagnostic performance criteria

Control points reside with regulators and payers, which dictate approval pathways and reimbursement models. Dependency risks include supply chain disruptions for critical reagents and interoperability challenges between diagnostic systems. Long-term partnerships between manufacturers and pharmaceutical firms are essential to align companion diagnostics with drug development, creating high switching costs. Regional variations in regulatory frameworks and adoption priorities further shape ecosystem dynamics.

Recent Industry Insights

The Oncology Companion Diagnostic industry trends over the past 18 months reflect accelerated innovation driven by precision medicine demands. Strategic partnerships have surged, with firms like Roche and Siemens Healthineers collaborating with biotech innovators to co-develop biomarker tests for immunotherapy and targeted therapies. Mergers & acquisitions also gained momentum, exemplified by Abbott’s acquisition of a molecular diagnostics startup to bolster its liquid biopsy portfolio. Product/technology launches highlight advancements in next-generation sequencing (NGS) panels, such as Guardant Health’s expanded liquid biopsy test for real-time tumor monitoring. Regulatory bodies, including the FDA, have streamlined companion diagnostic approvals by adopting adaptive trial frameworks and encouraging real-world evidence use, reducing time-to-market for novel tests. Meanwhile, a shift in enterprise trends prioritizes AI-driven data analytics to improve biomarker discovery and patient stratification. Funding rounds have spiked, with over $1.2 billion raised in 2023 by startups like Freenome and Tempus, fueling R&D in multi-omics and early cancer detection technologies. These developments underscore the sector’s trajectory toward faster, more personalized oncology care.

Analyst Overview

The Oncology Companion Diagnostic market outlook remains highly attractive, driven by the escalating adoption of personalized medicine and the rapid development of targeted therapies. With regulatory frameworks increasingly aligning with co-development pathways, the market is primed for sustained growth. However, competitive intensity is intensifying, as both established diagnostics firms and biopharma players vie for leadership in biomarker innovation and FDA approvals.

Key Insights4 items

Long-term outlook is optimistic, underpinned by rising cancer incidence and advancements in next-generation sequencing (NGS) technologies.

Innovation landscape is dynamic, with AI-driven analytics and liquid biopsy integration emerging as disruptive forces.

Demand-supply balance currently favors market stability, though scalability challenges may arise with the proliferation of novel biomarker tests.

Key risk factors include regulatory delays, reimbursement uncertainties, and the high R&D costs associated with complex diagnostic development.

Strategic collaborations and vertical integration will be critical for stakeholders to navigate this evolving landscape, ensuring alignment between diagnostic precision and therapeutic efficacy.

11 items

1. Executive Summary

2. Oncology Companion Diagnostic Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Oncology Companion Diagnostic Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Oncology Companion Diagnostic Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Pathology/Diagnostic Laboratory

6.1.3. Academic Medical Center

6.2. Global Oncology Companion Diagnostic Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Polymerase Chain Reaction (PCR)

6.2.2. Next-Generation Sequencing (NGS)

6.2.3. Immunohistochemistry (IHC)

6.2.4. In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)

6.2.5. Others

6.3. Global Oncology Companion Diagnostic Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Oncology Companion Diagnostic Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Oncology Companion Diagnostic Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Oncology Companion Diagnostic Market Competition by Key Manufacturers

8.1. Global Oncology Companion Diagnostic Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Oncology Companion Diagnostic: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Agilent Technologies, Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Illumina, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Qiagen N.V.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Thermo Fisher Scientific Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. F. Hoffmann-La Roche Ltd.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. ARUP Laboratories

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Abbott

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Myriad Genetics, Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. bioMérieux SA

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Invivoscribe, Inc.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Oncology Companion Diagnostic Market

Figure 4: Global Oncology Companion Diagnostic Market: Drivers

Figure 5: Global Oncology Companion Diagnostic Market: Challenges

Figure 6: Global Oncology Companion Diagnostic Market: Trends

Figure 7: Global Oncology Companion Diagnostic Market: Opportunity

Figure 8: Global Oncology Companion Diagnostic Market: Restraint

Figure 9: Global Oncology Companion Diagnostic Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Oncology Companion Diagnostic Market Value (USD Million) By Region

Figure 15: Global Oncology Companion Diagnostic Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Oncology Companion Diagnostic Market Value (USD Million) By Region

Figure 23: Global Oncology Companion Diagnostic Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Oncology Companion Diagnostic Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Oncology Companion Diagnostic Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Oncology Companion Diagnostic Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Oncology Companion Diagnostic Market Value (USD Million) By Region

Table 10: Global Oncology Companion Diagnostic Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Oncology Companion Diagnostic Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Oncology Companion Diagnostic Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Oncology Companion Diagnostic Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Agilent Technologies, Inc. Basic Information And Sales Area

Table 31: Agilent Technologies, Inc.. Products Portfolio

Table 32: Illumina, Inc. Basic Information And Sales Area

Table 33: Illumina, Inc.. Products Portfolio

Table 34: Qiagen N.V. Basic Information And Sales Area

Table 35: Qiagen N.V.. Products Portfolio

Table 36: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 37: Thermo Fisher Scientific Inc.. Products Portfolio

Table 38: F. Hoffmann-La Roche Ltd. Basic Information And Sales Area

Table 39: F. Hoffmann-La Roche Ltd.. Products Portfolio

Table 40: ARUP Laboratories Basic Information And Sales Area

Table 41: ARUP Laboratories. Products Portfolio

Table 42: Abbott Basic Information And Sales Area

Table 43: Abbott. Products Portfolio

Table 44: Myriad Genetics, Inc. Basic Information And Sales Area

Table 45: Myriad Genetics, Inc.. Products Portfolio

Table 46: bioMérieux SA Basic Information And Sales Area

Table 47: bioMérieux SA. Products Portfolio

Table 48: Invivoscribe, Inc. Basic Information And Sales Area

Table 49: Invivoscribe, Inc.. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Oncology Companion Diagnostic Market Value (USD Million) By Region

Table 55: Global Oncology Companion Diagnostic Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Oncology Companion Diagnostic Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	21.77 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Agilent Technologies, Inc.; Illumina, Inc.; Qiagen N.V.; Thermo Fisher Scientific Inc.; F. Hoffmann-La Roche Ltd.; ARUP Laboratories; Abbott; Myriad Genetics, Inc.; bioMérieux SA; Invivoscribe, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Oncology Companion Diagnostic Segmentation Breakdown10 items

Application

Hospital

Pathology/Diagnostic Laboratory

Academic Medical Center

Types

Polymerase Chain Reaction (PCR)

Next-Generation Sequencing (NGS)

Immunohistochemistry (IHC)

In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)

Others

Regional Insights

Loading chart…

Competitive Landscape

Agilent Technologies, Inc. — strategic pharma partnerships for co-development

Illumina, Inc. — expanding next-gen sequencing capacity in oncology

Qiagen N.V. — regional expansion via local manufacturing in Asia-Pacific

Thermo Fisher Scientific Inc. — vertical integration of diagnostic platforms

F. Hoffmann-La Roche Ltd. — portfolio diversification with multiplex assays

ARUP Laboratories — customization of service models for academic health systems

Key Oncology Companion Diagnostic Companies10 items

Agilent Technologies, Inc.

Illumina, Inc.

Qiagen N.V.

Thermo Fisher Scientific Inc.

F. Hoffmann-La Roche Ltd.

ARUP Laboratories

Abbott

Myriad Genetics, Inc.

bioMérieux SA

Invivoscribe, Inc.

Market Ecosystem

Raw material/component suppliers — provide reagents, antibodies, and substrates for assay development

Technology providers — develop molecular assay platforms and bioinformatics tools for biomarker detection

OEMs/manufacturers — produce diagnostic kits and devices for oncology-specific tests

System integrators — combine diagnostic hardware, software, and workflows for clinical deployment

Distributors/channel partners — manage supply chain logistics and commercialization in target markets

End users — hospitals, labs, and pharma companies that implement diagnostics for patient stratification

Regulators/standards bodies — oversee FDA/CE approval processes and harmonize diagnostic performance criteria

Recent Industry Insights

Analyst Overview

Key Insights4 items

Long-term outlook is optimistic, underpinned by rising cancer incidence and advancements in next-generation sequencing (NGS) technologies.

Innovation landscape is dynamic, with AI-driven analytics and liquid biopsy integration emerging as disruptive forces.

Demand-supply balance currently favors market stability, though scalability challenges may arise with the proliferation of novel biomarker tests.

Key risk factors include regulatory delays, reimbursement uncertainties, and the high R&D costs associated with complex diagnostic development.

Strategic collaborations and vertical integration will be critical for stakeholders to navigate this evolving landscape, ensuring alignment between diagnostic precision and therapeutic efficacy.

Table of Contents